What are the risks of 4-HO-MPT?

Acute Toxicity No formal toxicological data in humans. Class membership (4-hydroxy tryptamines, related to psilocin) predicts low acute physiological toxicity at psychedelic doses. No documented fatalities. Physiological Effects Standard tryptamine sympathomimetic effects: mydriasis, tachycardia, mi

How long does 4-HO-MPT last?

The total duration of 4-HO-MPT via oral is 5 hours to 7 hours. Onset typically occurs within 20 minutes to 1 hour. Peak effects last 2 hours to 3 hours.

4-HO-MPT — SubstanceWiki

4-HO-MPT (4-hydroxy-N-methyl-N-propyltryptamine) is a synthetic psychedelic tryptamine in the 4-hydroxy tryptamine family — structurally a higher homologue of psilocin (4-HO-DMT) with a propyl group replacing one of the two methyl groups on the terminal nitrogen. It is the direct free-phenol active form (rather than a prodrug like its acetylated counterpart 4-AcO-MPT), meaning it interacts directly with serotonin receptors without requiring metabolic activation.

Community experience reports describe 4-HO-MPT as a characteristically visual tryptamine with a quality of richness and emotional openness. Like other members of the methyl-alkyl substituted 4-HO tryptamine series, it is generally considered to have a somewhat distinct texture from psilocin — the propyl chain alters the receptor binding profile in ways that may contribute to a modestly different subjective emphasis. Duration is typically 4–6 hours.

4-HO-MPT remains a relatively obscure compound even within the psychedelic research chemical community. Its documentation is sparse compared to psilocin, 4-HO-MiPT, or 4-HO-MET, and formal pharmacological data are absent. Community reports and microdosing accounts represent the primary available data on its effects.

How It Feels

The onset of 4-HO-MPT establishes itself within twenty-five to forty minutes as a gradual brightening of the perceptual field. Colors become more distinct, contrasts sharpen, and there is a growing sense of visual crispness, as though a slightly fogged lens has been wiped clean. A moderate body buzz accompanies this brightening — tingling in the extremities, a mild warmth in the core, and occasional muscle tension in the shoulders and jaw. Nausea is possible but generally mild.

Over the next thirty to sixty minutes, the visual effects develop into their full expression. Surfaces acquire a gentle, breathing quality, expanding and contracting in slow rhythms. Patterns emerge in textures — repeating geometric motifs that overlay the visual field with moderate intensity. The patterns tend toward symmetry and order: tessellations, grids, and concentric forms that have a balanced, almost calming aesthetic. Colors shift toward greater saturation without dramatic hue changes. Closed-eye visuals offer more complexity: layered geometric structures, slowly rotating mandalas, and fields of patterned color that respond to music and breath.

The peak, arriving around ninety minutes to two hours and lasting two to three hours, presents a moderate psychedelic headspace. Thoughts are gently altered — more associative, more reflective, more inclined toward abstract consideration — but cognitive function remains largely intact. There is no heavy ego dissolution or confrontational introspection, but rather a contemplative spaciousness that invites curiosity without demanding submission. The body feels moderately stimulated, and physical comfort depends on the setting — movement feels good, and stillness is equally acceptable. Music is enhanced in both emotional resonance and spatial quality.

The comedown is gradual and uncomplicated, the visual patterning fading over one to two hours into a gentle shimmer and then back to baseline. The total duration is five to six hours. The afterglow is mild and pleasant — a slight brightening of mood and a calm, rested quality that may linger into the following day. 4-HO-MPT occupies a middle ground among tryptamines: more engaging than the gentlest members of the family, less demanding than the deepest, and offering a balanced, visually oriented experience that rewards without overwhelming.

Detection Methods

Urine Detection

4-HO-MPT is not targeted by standard immunoassay-based urine drug screens. Specialized LC-MS/MS methods can detect 4-substituted tryptamine metabolites in urine for approximately 24 to 48 hours after ingestion. The detection window is relatively short compared to many other drug classes due to the rapid hepatic metabolism and renal clearance of tryptamine compounds. Psilocin (4-HO-DMT) is the most commonly targeted analyte in specialized tryptamine panels, and structural analogs may or may not be captured depending on the specific method.

Blood and Serum Detection

Blood detection windows for 4-HO-MPT are short, typically 4 to 12 hours after oral ingestion. Peak plasma concentrations of the active metabolite occur within 1 to 2 hours. The rapid first-pass metabolism means that parent compound concentrations in blood are often negligible for 4-AcO prodrugs, while 4-HO compounds themselves are measured directly. LC-MS/MS is required for reliable serum detection at the low concentrations involved.

Standard Drug Panel Inclusion

4-HO-MPT is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. Tryptamines do not cross-react with immunoassay targets for any of the standard panel analytes (amphetamines, cannabinoids, cocaine metabolites, opiates, PCP, benzodiazepines, or barbiturates). Detection requires a specific request for tryptamine or novel psychoactive substance testing at a reference laboratory. Some extended forensic panels include psilocin, which may capture certain 4-substituted tryptamines, but this coverage is not guaranteed for all structural variants.

Confirmatory Methods

Confirmatory identification of 4-HO-MPT relies on LC-MS/MS with reference standards specific to the compound or its expected metabolites. GC-MS can also be used following appropriate derivatization. Immunoassay-based methods for psilocybin and psilocin exist but show variable cross-reactivity with structural analogs and are not considered reliable for novel 4-substituted tryptamines. Reference laboratories specializing in novel psychoactive substances offer the most comprehensive detection capabilities.

Reagent Testing (Harm Reduction)

The Ehrlich reagent is the primary harm reduction tool for 4-HO-MPT. A sample placed on the reagent should produce a purple to violet color change, confirming the presence of an indole ring system characteristic of tryptamines. This reaction is shared with LSD, psilocybin, DMT, and all indole-containing compounds, so it confirms the general class but not the specific identity. The Hofmann reagent provides a confirmatory blue to violet reaction for tryptamines. The Marquis reagent typically shows no reaction or a dark brown discoloration with 4-substituted tryptamines. A positive Ehrlich result significantly reduces the probability that the substance is a dangerous substitute such as an NBOMe compound.

Interactions

Substance	Status	Note
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabis	Uncertain	—
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 60 key interactions out of 79 total.

Full	almost immediately after ingestion
Half	3 days
Zero	7 days

4-HO-MPT

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(5)

Cognitive & Perceptual Effects

Visual(16)

Pharmacology

Direct 5-HT2A Agonism

Metabolic Stability

Pharmacokinetics

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Structural Background

Research Chemical Status

Harm Reduction

Dosing

Microdosing Context

Standard Psychedelic Harm Reduction

Toxicity & Safety

Acute Toxicity

Physiological Effects

Psychological Risks

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (3)

See Also

References (4)

Frequently Asked Questions

Cognitive(10)

Transpersonal(2)